(UroToday.com) The disease natural history of patients with biochemical recurrence following radical prostatectomy is varied – while some men will have an indolent course without treatment, others progress quickly in spite of aggressive therapy. Further, treatments are not without consequence in terms of cost, inconvenience, and morbidity. Thus, better understanding disease aggressivity to target treatment intensification would be valuable. TheDecipher® Genomic Classifier (GC) has been shown to independently prognosticate outcomes in prostate cancer. In the Prostate, Testicular, Penile Poster Discussion session at the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting held on Friday June 4th, 2021, Dr. Dal Pra presented an analysis validating the Decipher genomic classifier within the SAKK 09/10 trial.